Advertisement

Specification Setting for Drugs in the Pharmaceutical Industry

  • Jørgen Iwersen
  • Henrik Melgaard

Summary

In the pharmaceutical industry a drug must conform to certain limits through its shelf life period. To ensure compliance in practice we need manufacturing processes to be robust and in control, measurements systems to be in control and the measurements must be traceable. Storage conditions must be under control.

In this paper we discuss the practical implications involved in setting and maintaining specifications for drugs in the pharmaceutical industry. These include statistical process control limits, release limits, shelf life limits and in-use limits. The challenge here is to make this chain of limits consistent and at the same time be practical for use.

The scientific approach to establishing a chain of specifications involves normal linear mixed models and an Arrhenius model, a kinetic model, describing e.g. the temperature dependence of drug degradation. These models are applied to data from stability studies as well as data from batch release.

Keywords

Shelf Life Control Chart Drug Product Drug Substance Release Limit 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    ICH Topic Q6A, Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, July 1997.Google Scholar
  2. [2]
    ICH Topic Q6B, Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, CPMP/ICH/365/96, March 1999.Google Scholar
  3. [3]
    ICH Topic Q1A, Stability Testing of New Drugs and Products, CPMP/ICH/2736/99, March 2003.Google Scholar
  4. [4]
    Allan, Poul V. et al.: Determination of Release Limits: A General Methodology. Pharm. Res., 8(9), p 1210, 1991.CrossRefGoogle Scholar
  5. [5]
    ICH Topic Q1E, Evaluation of Stability Data, CPMP/ICH/420/02, March 2003.Google Scholar
  6. [6]
    Guide to the Expression of Uncertainty in Measurements.Google Scholar
  7. [7]
    Davis, Gregory C. et al.: Rational Approaches to Specifications Setting: An Opportunity for Harmonization. Pharm. Tech., September, 1995.Google Scholar
  8. [8]
    Wen-Jen Chen and Yi Tsong: Significance Levels for Stability Pooling Test: A Simulation Study, J.Biopharm. Stat. Vol. 13, No. 3, pp. 355–374, 2003.CrossRefGoogle Scholar

Copyright information

© Physica-Verlag Heidelberg 2006

Authors and Affiliations

  • Jørgen Iwersen
    • 1
  • Henrik Melgaard
    • 1
  1. 1.Novo AlléNovo Nordisk A/SBagsvaerdDenmark

Personalised recommendations